There are a few asterisks on that:
1. J&J used a somewhat broader case definition and a more aggressive testing regime than Moderna or Pfizer, which makes their numbers appear worse than they actually are in comparison.
2. That's after one dose. We don't have comparable single-dose data for Moderna/Pfizer, but what little data we do have is broadly comparable to J&J. Two-dose data for J&J should be out in the next month or so.









